Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the oral therapy. The financing will support completion of […]
The post Funding to support Immunic Phase 3 MS trials, commercialization appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com